Combined drug used for treating cancers

A drug and cancer technology, applied in the field of combined drugs for the treatment of cancer, can solve the problems of high toxicity and side effects, poor therapeutic effect, and poor selectivity of anti-malignant tumor drugs, achieve low toxicity, good clinical application prospects, and overcome toxic and side effects big effect

Active Publication Date: 2017-12-08
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the poor selectivity of anti-malignant tumor drugs, single-drug therapy has the disadvantages of large toxic side effects or poor therapeutic effect, so researching a new generation of low-toxicity and high-efficiency drugs has become an urgent task for the treatment of malignant tumors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined drug used for treating cancers
  • Combined drug used for treating cancers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 In vivo animal experiment of chlorogenic acid combined with fulvestrant to treat breast cancer in mice

[0020] 1. Materials

[0021] Test drugs: chlorogenic acid, fulvestrant.

[0022] Tested cell line: EMT-6 mouse breast cancer cell line.

[0023] Test animals: BALB / C-nu mice, ♀, body weight 16-21g.

[0024] 2. Experimental method

[0025] Take the cells in the logarithmic growth phase, digest them with trypsin until they are detached, and then add physiological saline to make a cell suspension. -1 (about 1×106 cells), inoculated under the left anterior armpit of mice, and randomly divided into groups according to body weight, respectively fulvestrant group, chlorogenic acid group, fulvestrant + chlorogenic acid combined drug group, Negative group, 6 rats in each group.

[0026] Fulvestrant was administered intraperitoneally once on the second day after inoculation; the chlorogenic acid group was administered intraperitoneally once a day from the second...

Embodiment 2

[0036] Example 2 In vivo animal experiments of chlorogenic acid combined with abarelix or degarelix in the treatment of prostate cancer in mice

[0037] 1. Materials

[0038] Test drugs: chlorogenic acid, abarelix, degarelix.

[0039] Tested cell line: RM-1 mouse prostate cancer cell line.

[0040] Test animals: Kunming mice, ♂, weighing 17-24 g.

[0041] 2. Experimental method

[0042] Take the cells in the logarithmic growth phase, digest them with trypsin until they are detached, and then add physiological saline to make a cell suspension. -1 (Containing about 1×106 cells), inoculated under the left anterior armpit of mice, and randomly divided into groups according to body weight, namely abarelix group, degarelix group, chlorogenic acid group, abarelix+green Ortho-acid combination group, degarelix + chlorogenic acid combination group, negative group, 6 rats in each group.

[0043] The abarelix group was given intraperitoneal injection once on the second day after inoc...

Embodiment 3

[0053] Example 3 Animal Experiments of Combining Chlorogenic Acid and Abarelix to Prepare Anti-multidrug Resistance

[0054] 1 material

[0055]Test drugs: chlorogenic acid, abarelix.

[0056] Tested cell line: RM-1 mouse prostate cancer cell line, which was induced by increasing the concentration of abarelix to RM-1 cell line, and established by clonal screening, and cultured without drug before the experiment.

[0057] Test animals: Kunming mice, ♂, weighing 17-24 g.

[0058] 2 Experimental methods

[0059] 2.1. Establishment of experimental animal tumor models

[0060] The drug-resistant cell lines after drug removal were adjusted to a cell concentration of 1×10 with culture medium. 7 / m1, inject 1×10 subcutaneously in the right armpit of mice 7 / ml of cells, each 0.1ml.

[0061] 2.2. Administration method

[0062] When the average diameter of the tumor reaches 100mm 3 Afterwards, the groups were divided into abarelix medication group, chlorogenic acid + abarelix gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a combined drug used for treating cancers. The combined drug contains chlorogenic acid and hormone drugs of the same or different unit dosages used for simultaneous or respective using, and pharmaceutically acceptable carriers. According to the combined drug, chlorogenic acid and hormone drugs are used together, so that synergistic interaction is achieved, defects of single drug treatment that toxic and side effect is obvious or curative effect is poor are avoided; the combined drug is excellent in curative effect, low in toxicity, is capable of reversing drug resistance on hormone drugs, and is promising in clinical application prospect.

Description

technical field [0001] The invention relates to a combined drug for treating cancer, belonging to the field of biotherapeutic drugs. Background technique [0002] Cancer is a major public health problem that needs to be solved urgently in China and all regions of the world. On average, millions of people are diagnosed with cancer every year, including more than 200 types of cancer. At present, cancer is the main cause of death one of the diseases. However, due to the poor selectivity of anti-cancer drugs, single-drug therapy has the disadvantages of large toxic side effects or poor therapeutic effect. Therefore, researching a new generation of low-toxicity and high-efficiency drugs has become an urgent task for the treatment of malignant tumors. [0003] Chlorogenic acid (Chlorogenic acid) is composed of caffeic acid (Caffeic acid) and quinic acid (Quinic acid) depsipphenolic acid, synonym caffeic tannic acid, chemical name 3-o-caffeoyl quinic acid (3-o -caffeoylquinic aci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/216A61K31/565A61K38/09A61P35/00
CPCA61K38/09A61K31/216A61K31/565A61K2300/00A61P35/00
Inventor 张洁黄望杨华蓉
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap